0001193125-23-240624.txt : 20230922 0001193125-23-240624.hdr.sgml : 20230922 20230922171253 ACCESSION NUMBER: 0001193125-23-240624 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230922 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20230922 DATE AS OF CHANGE: 20230922 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Galera Therapeutics, Inc. CENTRAL INDEX KEY: 0001563577 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 461454898 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39114 FILM NUMBER: 231272432 BUSINESS ADDRESS: STREET 1: 45 LIBERTY BLVD. STREET 2: SUITE 230 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 610-725-1500 MAIL ADDRESS: STREET 1: 45 LIBERTY BLVD. STREET 2: SUITE 230 CITY: MALVERN STATE: PA ZIP: 19355 8-K 1 d551276d8k.htm 8-K 8-K
false 0001563577 0001563577 2023-09-22 2023-09-22

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 22, 2023

 

 

GALERA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39114   46-1454898

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

45 Liberty Blvd #230

Malvern, PA 19355

(Address of principal executive offices) (Zip Code)

(610) 725-1500

(Registrant’s telephone number, include area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value per share   GRTX   The Nasdaq Stock Market LLC (Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

 

 

Item 3.01.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On September 22, 2023, Galera Therapeutics, Inc. (the “Company”) received two written notices (the “Notices”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that (i) the Company is no longer in compliance with the minimum Market Value of Listed Securities (“MVLS”) of $50,000,000 required for continued listing on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “Minimum MVLS Requirement”) and (ii) for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Notices have no effect at this time on the listing of the Common Stock, which continues to trade on The Nasdaq Global Market under the symbol “GRTX”.

In accordance with Nasdaq Listing Rule 5810(c)(3)(C) and Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until March 20, 2024 (the “Compliance Date”), to regain compliance with the Minimum MVLS Requirement and the Minimum Bid Price Requirement, respectively. To regain compliance with the Minimum MVLS Requirement, the Company’s MVLS must close at $50,000,000 or more for a minimum of 10 consecutive business days prior to the Compliance Date. To regain compliance with the Minimum Bid Price Requirement, the closing bid price of the Common Stock must be at least $1.00 per share for a minimum of 10 consecutive business days prior to the Compliance Date.

If the Company does not regain compliance with the Minimum MVLS Requirement by the Compliance Date, Nasdaq will notify the Company that its securities are subject to delisting, at which point the Company may appeal the delisting determination to a Nasdaq hearings panel. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, the Company may be eligible for a second 180 calendar day compliance period. To qualify, the Company must submit an application to transfer the listing of the Common Stock to The Nasdaq Capital Market, which requires the Company to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement. The Company would also need to pay an application fee to Nasdaq and to provide written notice of its intention to cure the deficiency during the additional compliance period. As part of its review process, Nasdaq will make a determination of whether it believes the Company will be able to cure this deficiency. If the Company does not qualify for or fails to regain compliance during the additional compliance period, then Nasdaq will notify the Company of its determination to delist its Common Stock, at which point the Company would have an opportunity to appeal the delisting determination to a Nasdaq hearings panel. There can be no assurance that, if the Company decides to appeal any delisting determination, such appeal would be successful.

The Company intends to actively monitor its MVLS and the closing bid price of its common stock and may, if appropriate, consider implementing available options to regain compliance with the Minimum MVLS Requirement and the Minimum Bid Price Requirement under the Nasdaq Listing Rules. There can be no assurance that the Company will be able to regain compliance with the Minimum MVLS Requirement or the Minimum Bid Price Requirement or maintain compliance with any other listing requirements.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s ability to regain compliance with the Minimum MVLS Requirement and the Minimum Bid Price Requirement, the Company’s intentions to actively monitor its MVLS and the closing bid price of its Common Stock and the Company’s plans to consider implementing available options to regain compliance with the Minimum MVLS Requirement and the Minimum Bid Price Requirement. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of important risks and uncertainties, including without limitation the risk that the Company may not meet the Minimum MVLS Requirement and the Minimum Bid Price Requirement during any compliance period or in the future, the risk that the Company may not otherwise meet the requirements for continued listing under the Nasdaq Listing

Rules, the risk that Nasdaq may not grant the Company relief from delisting if necessary, and the risk that the Company may not ultimately meet applicable Nasdaq requirements if any such relief is necessary, among other important risks and uncertainties. A further description of the risks and uncertainties relating to the business of the Company is contained in the Company’s most recent annual report on Form 10-K and the Company’s quarterly reports on Form 10-Q filed with the Securities and Exchange Commission. The Company undertakes no duty or obligation to update any forward-looking statements contained in this report as a result of new information, future events or changes in its expectations.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    GALERA THERAPEUTICS, INC.
Date: September 22, 2023     By:  

/s/ J. Mel Sorensen, M.D.

      J. Mel Sorensen, M.D.
      President and Chief Executive Officer
 EX-101.SCH 2 grtx-20230922.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 grtx-20230922_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 grtx-20230922_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Sep. 22, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001563577
Document Type 8-K
Document Period End Date Sep. 22, 2023
Entity Registrant Name GALERA THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-39114
Entity Tax Identification Number 46-1454898
Entity Address, Address Line One 45 Liberty Blvd #230
Entity Address, City or Town Malvern
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19355
City Area Code (610)
Local Phone Number 725-1500
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value per share
Trading Symbol GRTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
XML 6 d551276d8k_htm.xml IDEA: XBRL DOCUMENT 0001563577 2023-09-22 2023-09-22 false 0001563577 8-K 2023-09-22 GALERA THERAPEUTICS, INC. DE 001-39114 46-1454898 45 Liberty Blvd #230 Malvern PA 19355 (610) 725-1500 false false false false Common Stock, $0.001 par value per share GRTX NASDAQ true true EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d551276d8k.htm grtx-20230922.xsd grtx-20230922_lab.xml grtx-20230922_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d551276d8k.htm": { "nsprefix": "grtx", "nsuri": "http://www.galeratx.com/20230922", "dts": { "inline": { "local": [ "d551276d8k.htm" ] }, "schema": { "local": [ "grtx-20230922.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] }, "labelLink": { "local": [ "grtx-20230922_lab.xml" ] }, "presentationLink": { "local": [ "grtx-20230922_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "report": { "R1": { "role": "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-09-22_to_2023-09-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d551276d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-09-22_to_2023-09-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d551276d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://www.galeratx.com//20230922/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 13 0001193125-23-240624-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-240624-xbrl.zip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end